Centre Hospitalier Bethune Beuvry
- Address
- lock Available on a paid plan
Infectious Diseases and Critical Care
At Centre Hospitalier Bethune Beuvry, research in bacterial infections and virus diseases focuses on serious hospital-treated conditions such as sepsis, septic shock, and severe resistant infections. These studies aim to improve survival, protect organ function, and identify better treatment options for patients in intensive care.
- Severe infection management in ICU patients
- Sepsis and septic shock support therapies
- Strategies for resistant bacterial infections
Work in this area also includes evaluating whether alternative antimicrobial approaches can match standard care while reducing unnecessary broad-spectrum antibiotic use.
Oncology and Digestive System Cancers
Clinical trials in neoplasms and digestive system diseases explore cancers of the colon, rectum, pancreas, stomach, esophagus, and ampulla. The main goal is to test new treatment combinations and improve long-term control of advanced or resected disease.
- Colorectal cancer and biomarker-guided treatment
- Pancreatic and ampullary adenocarcinoma
- Gastric and esophageal cancers
Several studies are designed to strengthen disease-free survival and progression-free survival by refining how chemotherapy, targeted therapy, and immunotherapy are used.
Head and Neck Cancer Research
Another major area at the site is head and neck oncology, including squamous cell carcinoma of the oral cavity, pharynx, larynx, and related sites. These trials are examining new treatment combinations to improve disease control in locally advanced and recurrent settings.
- Locally advanced head and neck squamous cell carcinoma
- Radiotherapy combined with systemic treatments
- Post-surgical recurrence prevention
The research aims to make treatment more effective while preserving tolerability for patients facing complex cancers of the upper aerodigestive tract.
Neurology and Cognitive Disorders
Trials in nervous system diseases include research on Alzheimer's disease, with a focus on slowing cognitive decline and supporting day-to-day function. This work reflects an effort to find practical therapies that may help patients in the early to moderate stages of dementia.
- Alzheimer's disease and memory decline
- Symptom-focused treatment evaluation
- Support for cognitive preservation
These studies are centered on whether a simple therapeutic approach can offer measurable benefit for cognition and quality of life.
Physiological and Kidney-Related Research
Some studies address reproductive and urinary physiological phenomena and kidney-related complications, including patients with end-stage renal disease on dialysis and those who develop kidney injury during critical illness. The purpose is to better understand safety and treatment choices in medically fragile populations.
- Kidney complications during septic shock
- Anticoagulation in peritoneal dialysis patients
- Safety-focused care in complex chronic illness
At the site, this line of research supports more individualized care for patients with overlapping renal, infectious, and cardiovascular risks.
Bone and Joint Infection Research
Research also includes staphylococcal prosthetic joint infection, a difficult-to-treat form of bacterial infection affecting patients with implanted joints. The aim is to evaluate whether alternative oral treatments can maintain infection control during surgical and medical management.
- Prosthetic joint infection due to staphylococci
- Oral treatment options for infection control
- Improving practical care after joint surgery
This area highlights the site's interest in finding safer and more effective approaches for complex orthopedic infections.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 9 therapeutic areas and 15 of 51 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 48 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Bethune Beuvry
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Phase 2 Study of Adjunctive EQU-001 for Uncontrolled Focal Onset Seizures | Equilibre Biopharmaceuticals B.V. | Phase II | Not Recruiting | — | Jul 2023 |
IMP list
lock Showing 1 of 51 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 7 | Unknown | 2020-07-08 | 2026-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
